Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain.Park, J.H., Liu, Y., Lemmon, M.A., Radhakrishnan, R.
(2012) Biochem J 448: 417-423
- PubMed: 23101586
- DOI: https://doi.org/10.1042/BJ20121513
- Primary Citation of Related Structures:
- PubMed Abstract:
Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.
Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.